Inventiva Shares Rise on Diabetes Treatment Trial Results

Dow Jones

2025/01/23

By Katherine Hamilton

Inventiva shares climbed after the company said its treatment for diabetes and MASH appeared effective in a trial.

The stock was up 15% to $2.50 after the market close on Wednesday.

The biopharmaceutical company, which develops treatments for metabolic dysfunction-associated steatohepatitis (MASH), said a proof-of-concept trial met its primary efficacy endpoint.

The trial was evaluating the impact of a treatment for MASH and type-2 diabetes. Results demonstrated a significant reduction in HbA1c levels among patients.

The trial also showed therapeutic efficacy with statistical significance across multiple secondary endpoints, including markers of liver injury, glucose and lipid metabolism and hepatic steatosis.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

January 22, 2025 17:24 ET (22:24 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2505070730"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2505070730\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2505070730?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-23 06:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2505070730","market":"us","top_or_hot":-1,"title":"Inventiva Shares Rise on Diabetes Treatment Trial Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  Inventiva shares climbed after the company said its treatment for diabetes and MASH appeared effective in a trial. \n</p>\n<p>\n  The stock was up 15% to $2.50 after the market close on Wednesday. \n</p>\n<p>\n  The biopharmaceutical company, which develops treatments for metabolic dysfunction-associated steatohepatitis (MASH), said a proof-of-concept trial met its primary efficacy endpoint. \n</p>\n<p>\n  The trial was evaluating the impact of a treatment for MASH and type-2 diabetes. Results demonstrated a significant reduction in HbA1c levels among patients. \n</p>\n<p>\n  The trial also showed therapeutic efficacy with statistical significance across multiple secondary endpoints, including markers of liver injury, glucose and lipid metabolism and hepatic steatosis. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 22, 2025 17:24 ET (22:24 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inventiva Shares Rise on Diabetes Treatment Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInventiva Shares Rise on Diabetes Treatment Trial Results\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-01-23 06:24</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  Inventiva shares climbed after the company said its treatment for diabetes and MASH appeared effective in a trial. \n</p>\n<p>\n  The stock was up 15% to $2.50 after the market close on Wednesday. \n</p>\n<p>\n  The biopharmaceutical company, which develops treatments for metabolic dysfunction-associated steatohepatitis (MASH), said a proof-of-concept trial met its primary efficacy endpoint. \n</p>\n<p>\n  The trial was evaluating the impact of a treatment for MASH and type-2 diabetes. Results demonstrated a significant reduction in HbA1c levels among patients. \n</p>\n<p>\n  The trial also showed therapeutic efficacy with statistical significance across multiple secondary endpoints, including markers of liver injury, glucose and lipid metabolism and hepatic steatosis. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 22, 2025 17:24 ET (22:24 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IVA","symbol_name":"Inventiva S.A.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2505070730","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2505070730","pubTimestamp":1737584640,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Inventiva shares climbed after the company said its treatment for diabetes and MASH appeared effective in a trial.The stock was up 15% to $2.50 after the market close on Wednesday.The biopharmaceutical company, which develops treatments for metabolic dysfunction-associated steatohepatitis , said a proof-of-concept trial met its primary efficacy endpoint.The trial was evaluating the impact of a treatment for MASH and type-2 diabetes. Results demonstrated a significant reduction in HbA1c levels among patients.The trial also showed therapeutic efficacy with statistical significance across multiple secondary endpoints, including markers of liver injury, glucose and lipid metabolism and hepatic steatosis.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IVA":"Inventiva S.A.","BK4139":"生物科技"},"translate_title":"Inventiva股价因糖尿病治疗试验结果而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IVA":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Inventiva shares climbed after the company said its treatment for diabetes and MASH appeared effective in a trial. \n\n\n  The stock was up 15% to $2.50 after the market close on Wednesday. \n\n\n  The biopharmaceutical company, which develops treatments for metabolic dysfunction-associated steatohepatitis (MASH), said a proof-of-concept trial met its primary efficacy endpoint. \n\n\n  The trial was evaluating the impact of a treatment for MASH and type-2 diabetes. Results demonstrated a significant reduction in HbA1c levels among patients. \n\n\n  The trial also showed therapeutic efficacy with statistical significance across multiple secondary endpoints, including markers of liver injury, glucose and lipid metabolism and hepatic steatosis. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 22, 2025 17:24 ET (22:24 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}